Abbott Laboratories Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Abbott Laboratories Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 27 Jun 2017 | Lorem |
| TG Therapeutics’ GENUINE CLL trial data supportive of accelerated approval despite protocol amendment concerns – experts | 28 Mar 2017 | Alaric DeArment |
| AbbVie/Roche's Venclexta has solid backing for Rituxan combination in CLL, positive Phase III trial – experts | 17 Mar 2017 | Alaric DeArment |
| AstraZeneca’s durvalumab/tremelimumab Phase III NSCLC dosing regimen should boost safety profile though toxicity caution remains - experts | 16 Feb 2017 | Hamish McDougall |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer